229 related articles for article (PubMed ID: 28486596)
21. The profile of bile acids and their sulfate metabolites in human urine and serum.
Bathena SP; Mukherjee S; Olivera M; Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 942-943():53-62. PubMed ID: 24212143
[TBL] [Abstract][Full Text] [Related]
22. Basal efflux of bile acids contributes to drug-induced bile acid-dependent hepatocyte toxicity in rat sandwich-cultured hepatocytes.
Susukida T; Sekine S; Ogimura E; Aoki S; Oizumi K; Horie T; Ito K
Toxicol In Vitro; 2015 Oct; 29(7):1454-63. PubMed ID: 26055650
[TBL] [Abstract][Full Text] [Related]
23. Troglitazone.
Yokoi T
Handb Exp Pharmacol; 2010; (196):419-35. PubMed ID: 20020270
[TBL] [Abstract][Full Text] [Related]
24. Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition.
Cepa S; Potter D; Wong L; Schutt L; Tarrant J; Pang J; Zhang X; Andaya R; Salphati L; Ran Y; An L; Morgan R; Maher J
Toxicol Appl Pharmacol; 2018 Jan; 338():204-213. PubMed ID: 29146462
[TBL] [Abstract][Full Text] [Related]
25. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity.
Marion TL; Leslie EM; Brouwer KL
Mol Pharm; 2007; 4(6):911-8. PubMed ID: 17963355
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of Cellular Accumulation of Hydrophobic Bile Acids As a Marker of Cholestatic Drug Potential.
Burban A; Sharanek A; Humbert L; Eguether T; Guguen-Guillouzo C; Rainteau D; Guillouzo A
Toxicol Sci; 2019 Apr; 168(2):474-485. PubMed ID: 30629237
[TBL] [Abstract][Full Text] [Related]
27. Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury.
Yang K; Pfeifer ND; Köck K; Brouwer KL
J Pharmacol Exp Ther; 2015 May; 353(2):415-23. PubMed ID: 25711339
[TBL] [Abstract][Full Text] [Related]
28. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.
Yang K; Woodhead JL; Watkins PB; Howell BA; Brouwer KL
Clin Pharmacol Ther; 2014 Nov; 96(5):589-98. PubMed ID: 25068506
[TBL] [Abstract][Full Text] [Related]
29. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice.
Song P; Zhang Y; Klaassen CD
Toxicol Sci; 2011 Oct; 123(2):359-67. PubMed ID: 21747115
[TBL] [Abstract][Full Text] [Related]
30. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
[TBL] [Abstract][Full Text] [Related]
31. In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury.
Usui T; Hashizume T; Katsumata T; Yokoi T; Komuro S
Drug Metab Dispos; 2011 Jul; 39(7):1303-10. PubMed ID: 21511944
[TBL] [Abstract][Full Text] [Related]
32. Species differences in bile acids I. Plasma and urine bile acid composition.
Thakare R; Alamoudi JA; Gautam N; Rodrigues AD; Alnouti Y
J Appl Toxicol; 2018 Oct; 38(10):1323-1335. PubMed ID: 29785833
[TBL] [Abstract][Full Text] [Related]
33. Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors.
Kis E; Ioja E; Nagy T; Szente L; Herédi-Szabó K; Krajcsi P
Drug Metab Dispos; 2009 Sep; 37(9):1878-86. PubMed ID: 19520776
[TBL] [Abstract][Full Text] [Related]
34. Rat precision-cut liver slices predict drug-induced cholestatic injury.
Starokozhko V; Greupink R; van de Broek P; Soliman N; Ghimire S; de Graaf IAM; Groothuis GMM
Arch Toxicol; 2017 Oct; 91(10):3403-3413. PubMed ID: 28391356
[TBL] [Abstract][Full Text] [Related]
35. Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures.
Liu J; Lu H; Lu YF; Lei X; Cui JY; Ellis E; Strom SC; Klaassen CD
Toxicol Sci; 2014 Oct; 141(2):538-46. PubMed ID: 25055961
[TBL] [Abstract][Full Text] [Related]
36. Troglitazone-associated hepatic failure.
Misbin RI
Ann Intern Med; 1999 Feb; 130(4 Pt 1):330. PubMed ID: 10068399
[No Abstract] [Full Text] [Related]
37. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.
Graham DJ; Drinkard CR; Shatin D
Am J Gastroenterol; 2003 Jan; 98(1):175-9. PubMed ID: 12526954
[TBL] [Abstract][Full Text] [Related]
38. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
39. CYP7A1 Gene Induction via SHP-Dependent or Independent Mechanisms can Increase the Risk of Drug-Induced Liver Injury Independently or in Synergy with BSEP Inhibition.
Niu C; Xie X; Liu R; Liang X; Hu Y; Lai Y
Drug Metab Dispos; 2024 Apr; 52(5):432-441. PubMed ID: 38485279
[TBL] [Abstract][Full Text] [Related]
40. Urinary bile acids as biomarkers for liver diseases II. Signature profiles in patients.
Bathena SP; Thakare R; Gautam N; Mukherjee S; Olivera M; Meza J; Alnouti Y
Toxicol Sci; 2015 Feb; 143(2):308-18. PubMed ID: 25344563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
